HRAS

GTPase HRas · P01112 · HRAS on Sugi Atlas →

9,224 patent compounds predicted against HRAS, 5,623 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Stallimycin (SCHEMBL108585)	1.00	14/20
Hydrochloric Acid (SCHEMBL4618436)	1.00	14/20
Stallimycin (SCHEMBL193003)	0.98	14/20
Tallimustine (SCHEMBL1230144)	0.82	14/20
Tallimustine (SCHEMBL62279)	0.82	14/20
Hydrochloric Acid (SCHEMBL4621620)	0.76	14/20
SCHEMBL4620840	0.76	14/20
SCHEMBL4857581	0.74	14/20
Netropsin (SCHEMBL197747)	0.71	14/20
Hydrochloric Acid (SCHEMBL1652138)	0.71	14/20
SCHEMBL3672404	0.70	14/20
SCHEMBL3680040	0.70	14/20
Netropsin (SCHEMBL4953090)	0.70	14/20
Netropsin (SCHEMBL951644)	0.69	14/20
Hydrochloric Acid (SCHEMBL3454493)	0.69	14/20
Hydrochloric Acid (SCHEMBL3455291)	0.69	14/20
SCHEMBL3685005	0.61	14/20
Hydrochloric Acid (SCHEMBL3454819)	0.60	14/20
SCHEMBL3678651	0.60	14/20
Hydrochloric Acid (SCHEMBL3454587)	0.59	14/20

Clinical trials — most relevant to HRAS by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer	PHASE2/PHASE3	COMPLETED
Phase II Trial of Tunlametinib in Patients With NRAS Mutant Non-melanoma Refractory Solid Tumors	PHASE2	RECRUITING
BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer	PHASE2	COMPLETED
Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS	PHASE2	RECRUITING
Selumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By Surgery	PHASE2	COMPLETED
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS	PHASE1/PHASE2	RECRUITING
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma	PHASE1/PHASE2	RECRUITING
NEO100 and High-Grade Meningioma	PHASE2	RECRUITING
SBRT Plus Pembrolizumab and Trametinib for Pancreatic Cancer	PHASE2	COMPLETED
A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation	PHASE1/PHASE2	RECRUITING
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma	PHASE1/PHASE2	SUSPENDED
Efficacy and Safety of Cetuximab in Metastatic Penile Carcinoma (PENILANE)	PHASE2	WITHDRAWN
A Study of HRS-4642 in Combination With Antineoplastic Agents in Advanced Solid Tumors	PHASE1/PHASE2	RECRUITING
PiCCA Study (Panitumumab in Combination With Cisplatin/Gemcitabine)	PHASE2	COMPLETED
SUTENT (SUNITINIB, SU11248)in Patients With Recurrent or Progressive Glioblastoma Multiforme	PHASE2	UNKNOWN
A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations	PHASE1/PHASE2	RECRUITING
Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin for Non-Small Cell Lung Cancer With KRAS or EGFR Activation	PHASE2	COMPLETED
Phase I Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation	PHASE1	ACTIVE_NOT_RECRUITING
Application of KRAS Vaccine in the Treatment of KRAS-mutated Malignancies	PHASE1	RECRUITING
A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma	PHASE1	ACTIVE_NOT_RECRUITING
Phase I - Escalating Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Locally Advanced Adenocarcinoma of the Pancreas, and a Single Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Non-operable Adenocarcinoma of the Pancreas	PHASE1	COMPLETED
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors	PHASE1	ACTIVE_NOT_RECRUITING
Phase I Study of HRS-6093 in Participants With Advanced Solid Tumors Harboring KRAS G12D Mutations	PHASE1	RECRUITING
A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors	PHASE1	RECRUITING
Expression and Function of the Renin-Angiotensin System in the Esophagus	EARLY_PHASE1	COMPLETED
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies	nan	RECRUITING
Clinical Genetics Branch Eligibility Screening Survey	nan	NOT_YET_RECRUITING
Prospective Validation of a DNA Damage Repair-Hippo Pathway Signature in Patients With Advanced Gastric Cancer	nan	UNKNOWN
Pancreatic Cancer Screening of High-Risk Individuals in Arkansas	nan	WITHDRAWN

Related proteins — ESM-2 sequence neighbours (a HRAS binder may also engage these)

Protein	Name	Similarity
P20171	—	1.000	P20171 →
Q61411	—	1.000	Q61411 →
P08642	—	1.000	P08642 →
P23175	—	1.000	P23175 →
Q95ME4	—	1.000	Q95ME4 →
Q2MJK3	—	1.000	Q2MJK3 →
P01113	—	1.000	P01113 →
P12825	—	1.000	P12825 →
P05774	—	1.000	P05774 →
Q04970	—	1.000	Q04970 →
P79737	—	1.000	P79737 →
NRAS	GTPase NRas	1.000	landscape →
P08644	—	1.000	P08644 →
P32883	—	1.000	P32883 →
P18262	—	1.000	P18262 →
P08556	—	1.000	P08556 →
Q5RD87	—	0.999	Q5RD87 →
KRAS	GTPase KRas	0.999	landscape →
Q05147	—	0.999	Q05147 →
Q5F352	—	0.999	Q5F352 →
P83831	—	0.998	P83831 →
Q5EFX7	—	0.998	Q5EFX7 →
Q9YH38	—	0.998	Q9YH38 →
O42277	—	0.998	O42277 →
Q91806	—	0.997	Q91806 →
P22981	—	0.997	P22981 →
B4GFJ8	—	0.996	B4GFJ8 →
B3M185	—	0.996	B3M185 →
B3NZR4	—	0.996	B3NZR4 →
B4PUP5	—	0.996	B4PUP5 →